Biological factors that impinge on Chagas disease drug development
- PMID: 28831944
- PMCID: PMC5729846
- DOI: 10.1017/S0031182017001469
Biological factors that impinge on Chagas disease drug development
Abstract
Chagas disease is caused by infection with the insect-transmitted protozoan Trypanosoma cruzi, and is the most important parasitic infection in Latin America. The current drugs, benznidazole and nifurtimox, are characterized by limited efficacy and toxic side-effects, and treatment failures are frequently observed. The urgent need for new therapeutic approaches is being met by a combined effort from the academic and commercial sectors, together with major input from not-for-profit drug development consortia. With the disappointing outcomes of recent clinical trials against chronic Chagas disease, it has become clear that an incomplete understanding of parasite biology and disease pathogenesis is impacting negatively on the development of more effective drugs. In addition, technical issues, including difficulties in establishing parasitological cure in both human patients and animal models, have greatly complicated the assessment of drug efficacy. Here, we outline the major questions that need to be addressed and discuss technical innovations that can be exploited to accelerate the drug development pipeline.
Keywords: Trypanosoma cruzi; Chagas disease; disease pathogenesis; drug development.
Figures
References
-
- Assíria Fontes Martins T., de Figueiredo Diniz L., Mazzeti A. L., da Silva do Nascimento Á. F., Caldas S., Caldas I. S., de Andrade I. M., Ribeiro I. and Bahia M. T. (2015). Benznidazole/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease. PLoS ONE 10, e0128707. - PMC - PubMed
-
- Bellotti G., Bocchi E. A., de Moraes A. V., Higuchi M. L., Barbero-Marcial M., Sosa E., Esteves-Filho A., Kalil R., Weiss R., Jatene A. and Pileggi F. (1996). In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. American Heart Journal 131, 301–307. - PubMed
-
- Benvenuti L. A., Roggério A., Nishiya A. S., Campos S. V., Fiorelli A. I. and Levi J. E. (2014). Trypanosoma cruzi persistence in the native heart is associated with high-grade myocarditis, but not with Chagas’ disease reactivation after heart transplantation. The Journal of Heart and Lung Transplantation 33, 698–703. - PubMed
-
- Bermejo D. A., Amezcua Vesely M. C., Khan M., Acosta Rodríguez E. V., Montes C. L., Merino M. C., Toellner K. M., Mohr E., Taylor D., Cunningham A. F. and Gruppi A. (2011). Trypanosoma cruzi infection induces a massive extrafollicular and follicular splenic B-cell response which is a high source of non-parasite-specific antibodies. Immunology 132, 123–133. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
